SCHEMBL6076329

SCHEMBL6076329

Cc1nc2c(C)cc(Br)cc2c(OCc2ccccc2)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.40
ATP4A P20648 2/20 0.40
ATP4B P51164 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MAOB P27338 1/20 0.38
NQO2 P16083 1/20 0.38
TSHR P16473 1/20 0.38
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PARP1 P09874 1/20 0.37
PARP2 Q9UGN5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16651446 0.81 GAA (0.38) SMN1; SMN2STAT3HTTL3MBTL1MAPT
SCHEMBL6077263 0.78 TSHR (0.36) SMN1; SMN2STAT3HTTATP4AATP4B
SCHEMBL16652098 0.77 RORC (0.47) SMN1; SMN2ATP4AATP4BL3MBTL1MAPT
SCHEMBL348875 0.77 MEN1 (0.55) SMN1; SMN2L3MBTL1MAPTGAAHPGD
SCHEMBL6077445 0.76 THRA (0.42) SMN1; SMN2STAT3HTTL3MBTL1MAPT
SCHEMBL6077441 0.76 TDP1 (0.36) SMN1; SMN2STAT3HTTATP4AATP4B
SCHEMBL26608216 0.75 L3MBTL1 (0.47) SMN1; SMN2STAT3HTTATP4AATP4B
SCHEMBL3103639 0.73 L3MBTL1 (0.50) SMN1; SMN2STAT3HTTL3MBTL1MAPT
SCHEMBL3092046 0.72 MAPT (0.42) SMN1; SMN2STAT3HTTMAPTGAA
SCHEMBL13096638 0.72 HTT (0.42) SMN1; SMN2STAT3HTTL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067668-B2 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture MEIJI SEIKA KAISHA, LTD. (JP) 2006-06-27 US disclosed
EP-0990648-B1 4-QUINOLINOL DERIVATIVES AND AGROHORTICULTURAL BACTERICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA (JP) 2005-11-02 EP disclosed
US-20040152728-A1 4-Quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-05 US disclosed
US-6680282-B2 FUNGICIDE HAVING AN EXCELLENT CONTROL EFFECT; 4-QUINOLINOL DERIVATIVES HAVING SPECIFIC SUBSTITUENT AT 1,2 AND ATLEAST ONE SUBSTITUENT AT 5,6,7,8 POSITION MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-20 US disclosed
US-20030119863-A1 4-Quinolinol derivatives and agrohorticultural bactericides containing the same as active ingredient MEIJI SEIKA PHARMA CO., LTD. (JP) 2003-06-26 US disclosed
EP-0990648-A1 4-QUINOLINOL DERIVATIVES AND AGROHORTICULTURAL BACTERICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT Meiji Seika Kaisha, Ltd. (JP) 2000-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152728-A1 4-Quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture CYP51A1, CYP4X1, CYP4Z1 SMN1; SMN2 4492/4885STAT3 3195/4885HTT 1245/4885
US-20030119863-A1 4-Quinolinol derivatives and agrohorticultural bactericides containing the same as active ingredient CYP51A1, DDT, PGLS SMN1; SMN2 4579/4885STAT3 2947/4885HTT 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.